Stock events for Cadrenal Therapeutics, Inc. (CVKD)
Over the past six months, Cadrenal Therapeutics' stock has experienced significant declines and volatility. Key events impacting the stock price include the Third Quarter 2025 Financial Results, an At-the-Market (ATM) Stock Sale, the Acquisition of VLX-1005, First Quarter 2025 Earnings, Second Quarter 2025 Financial Results, and general stock performance.
Demand Seasonality affecting Cadrenal Therapeutics, Inc.’s stock price
Information regarding demand seasonality for Cadrenal Therapeutics, Inc.'s products and services is not available in the provided search results.
Overview of Cadrenal Therapeutics, Inc.’s business
Cadrenal Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Ponte Vedra, Florida, focused on developing innovative anticoagulation therapies. The company's primary product candidates include Tecarfarin, an oral vitamin K antagonist (VKA) designed for chronic use; Frunexian, a parenteral Factor XIa inhibitor being developed for acute hospital settings; and VLX-1005, a Phase 2 drug candidate for Heparin-Induced Thrombocytopenia (HIT).
CVKD’s Geographic footprint
Cadrenal Therapeutics, Inc. is headquartered in Ponte Vedra, Florida, United States, with operations and development efforts primarily focused within the U.S. market.
CVKD Corporate Image Assessment
Cadrenal Therapeutics received positive recognition in November 2024, being named the "Anticoagulation Therapy Company of the Year" by Pharma Tech Outlook, which positively impacted its brand reputation within the pharmaceutical technology industry.
Ownership
Cadrenal Therapeutics, Inc. has 28 institutional owners and shareholders holding a total of 120,158 shares. Institutional investors hold 7.9% of outstanding shares, while company insiders control 26.1% of the total shares, indicating a concentrated ownership structure. Major institutional shareholders include Vanguard Group Inc., VTSMX - Vanguard Total Stock Market Index Fund Investor Shares, Citadel Advisors Llc, VEXMX - Vanguard Extended Market Index Fund Investor Shares, LPL Financial LLC, Geode Capital Management, Llc, Jpmorgan Chase & Co, BlackRock, Inc., IWC - iShares Micro-Cap ETF, and DFSU - Dimensional US Sustainability Core 1 ETF.
Ask Our Expert AI Analyst
Price Chart
$6.71
